ADC Therapeutics SA公布,其药物Zynlonta与利妥昔单抗联合疗法,在关键临床研究LOTIS-5中,成功达到了无进展生存期这一主要终点的统计学显著性。
ADC Therapeutics SA公布,其药物Zynlonta与利妥昔单抗联合疗法,在关键临床研究LOTIS-5中,成功达到了无进展生存期这一主要终点的统计学显著性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.